Yarrow Bioscience, Inc. (YARW)
40.85
+1.60
(+4.08%)
USD |
NASDAQ |
Aug 26, 12:09
Yarrow Bioscience Total Liabilities (Quarterly) : 1.542M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.542M |
| March 31, 2026 | 1.236M |
| December 31, 2025 | 2.395M |
| September 30, 2025 | 4.044M |
| June 30, 2025 | 5.836M |
| March 31, 2025 | 12.29M |
| December 31, 2024 | 14.82M |
| September 30, 2024 | 12.66M |
| June 30, 2024 | 11.78M |
| March 31, 2024 | 8.306M |
| December 31, 2023 | 8.95M |
| September 30, 2023 | 7.762M |
| June 30, 2023 | 7.687M |
| March 31, 2023 | 7.532M |
| December 31, 2022 | 9.345M |
| September 30, 2022 | 6.839M |
| June 30, 2022 | 6.835M |
| March 31, 2022 | 8.588M |
| December 31, 2021 | 18.41M |
| September 30, 2021 | 22.43M |
| Date | Value |
|---|---|
| June 30, 2021 | 59.09M |
| March 31, 2021 | 56.27M |
| December 31, 2020 | 56.25M |
| September 30, 2020 | 58.17M |
| June 30, 2020 | 59.31M |
| March 31, 2020 | 91.00M |
| December 31, 2019 | 63.58M |
| September 30, 2019 | 9.574M |
| June 30, 2019 | 12.21M |
| March 31, 2019 | 10.63M |
| December 31, 2018 | 9.551M |
| September 30, 2018 | 8.074M |
| June 30, 2018 | 8.727M |
| March 31, 2018 | 14.78M |
| December 31, 2017 | 14.57M |
| September 30, 2017 | 14.43M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 12.49M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Oramed Pharmaceuticals, Inc. | 52.17M |
| NRX Pharmaceuticals, Inc. | 34.33M |
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 23.60M |
| Shareholders Equity (Quarterly) | 22.06M |
| Current Ratio | 15.26 |
| Net Debt Paydown Yield | 0.06% |